OBJECTIVES: Many veterinarians are hesitant to recommend cefovecin sodium for subcutaneous administration as a first treatment for superficial pyoderma in dogs because there is a perception that dog owners will not accept the cost compared to less expensive oral medications requiring repeated administration.  The objective  was to assess the impact of weight of the dog using a margin markup pricing method on the acceptance by dog owners of cefovecin sodium as a first line treatment in appropriate cases. METHODS: Thirty veterinarians in 22 different geographical veterinary practices that were members of CAPNA a group of veterinary hospitals owned by veterinarians in the US were asked to offer cefovecin sodium as a first line treatment for appropriate cases. The date of examination, weight of the dog and owner’s acceptance or decline was recorded for a two month period.  Owners were charged using  the weight of the dog multiplied by 1.25 plus a $45 margin markup . RESULTS: Of the sample of 683 dogs, 76.28% (n=521) accepted cefovecin sodium as a single subcutaneous administration with an average weight of 32.57 lbs and a range of 3-135 lbs.  23.7% (n=162) declined treatment with an average weight of 58.44 lbs with a range of 10.20-155 lbs. The difference in weights of 25.87 lbs  was statistically significant (P< 0.0001). The average cost of the accepted cefovecin sodium injection for 32.57 lb dog is $85.71. The average cost of the declined cefovecin sodium injection is $118.05.The average cost of the alternative oral medications for cefpodoxime proxetil administered once daily is $29.96  and cephalexin administered twice daily is $5.04. CONCLUSIONS: The dog owners in this study accepted treatment with  cefovecin sodium as a first line of therapy in 76.2% of the cases even though the cost of the onetime treatment was 3 to17 times more than oral alternatives.